Aadesh Mahendra Pirgal’s Post

📢 BREAKING NEWS 📢 Hasten Announces Acquisition of 14 Celltrion Legacy Products, Accelerating its Business Expansion in the Pan-Asia Area. Hasten Biopharmaceutical Co., Ltd. (Hasten) announced today that it has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a Korean biopharmaceutical company. According to the agreement, Hasten will also own the Marketing Authorization Holder (MAH) rights for these products in 8 countries and regions, including South Korea(Excluding Nesina®, Edarbi® and Actos®), Singapore, Thailand, Australia, China Hong Kong S.A.R.. The deal will enrich Hasten's product pipeline across 8 countries and regions outside mainland China, combined with more qualified global supply chain and a quality management system, which will surely pave the way for access to more high-quality products in the Pan-Asia Area. "This acquisition is strategically important to Hasten's continued growth and we're delighted to be part of the company's expansion journey." Fu Wei, CEO of CBC Group stated, "Driven by the dual forces of 'Hasten Speed' and 'Hasten Power', the company is well-positioned to tap into more potentials and benefit more patients. Moving forward, we will continue to leverage our unique 'Investor-Operator' approach to support Hasten in making a collective impact. By joining forces, we aim to build a health ecosystem spanning the Pan-Asia region and beyond, providing high-quality treatments and services to more patients, contributing to the development of the global healthcare industry." Summer XIA Shaofei, CEO of Hasten, said, "This acquisition marks a significant step in Hasten's business expansion in Pan-Asia and serves as an important milestone of our globalization trajectory. By expanding a commercial layout spanning multiple regions in Pan-Asia and covering more classic products, we have broadened Hasten's product portfolio while paving the ways for more high-quality products accessing Pan-Asia. This aligns with Hasten's development strategy of 'Pursuing Steady Progress'. We will continue to make full use of our commercialization capability and innovative business models to serve patients in Pan-Asia and even globally with quality products and solutions, so as to create the social health value." https://lnkd.in/gvarVMWz #Hasten #PanAsia #Healthcare #goingoverseas #globalization

INCHAM CORPORATE MEMBER ENTERS INDIAN MARKET WITH ACQUISITION OF CELIN & SEPTRAN The Indian pharmaceutical market is flourishing, driven by strong R&D and a strategic focus on ASEAN and India for exporting to European and US markets. Leading this charge is RV Group, an INCHAM Corporate Member. RV Group is a multinational pharmaceutical powerhouse with over 3,500 employees across nine countries. Founded in 2006, RV Group has become dominant in ASEAN, CIS, and now plans to enter the US market. Chairman Rajiv Sharma notes that their journey started from Vietnam to ASEAN and then to a global presence. RV Group’s strategic merger with KCH and acquisition of legacy brands Celin & Septran enhances their Indian market position. This move, combined with RV's manufacturing and marketing expertise is expected to grow healthcare demands in India and impacts the global pharmaceutical landscape. Reference: ET Health World #inchamhanoi #RVGroup #member #healthcare #pharmaceutical

IPO series 67/n Founded in 1998, Indegene Ltd. provides digital-led commercialization services for the life sciences industry, assisting with drug development, clinical trials, regulatory submissions, complaints management, and sales & marketing for their products. The company enjoys a virtual monopoly in its business and accounts for ~98% of global revenue for such services in the verticals it operates in. It has established client relationships with each of the 20 largest biopharmaceutical companies in the world by revenue in FY23. The IPO currently has a Grey Market Premium (GMP) of Rs. 255 (~56% above the higher end of price range of Rs. 452) and has already been subscribed 7.7 times as of today (8th May 2024) IPO opened on Monday (6th May 2024) and closes today, Wednesday (8th May 2024). Disclaimer: Abhiyaan Wealth is not associated with the company or a beneficiary of this IPO in any way. We do not claim accuracy of the data, which has been sourced from publicly available information. This is for educational purposes only and any investor should discuss with their financial advisor, prior to applying in the IPO. #finance #investing #ipoalert #equity #savetoinvestabhiyaan #abhiyaanwealth #mutualfundsabhiyaan #indegene #ipo

💼 Breaking News in Pharma! 💊 Suven Pharmaceuticals, a leading name in the Indian pharmaceutical industry, is set to make waves globally by acquiring a 56% stake in a US-based firm for $64.4 million! 🌍💸 This strategic move demonstrates Suven’s commitment to expanding its global footprint and strengthening its position in the pharmaceutical value chain. Such acquisitions reflect the growing impact of Indian pharma on the global stage, paving the way for innovative collaborations and growth opportunities. As a passionate student of Pharmaceutical and Healthcare Management, I find this news truly inspiring! It highlights how strategic investments and acquisitions can drive growth, innovation, and international partnerships. 👉 What are your thoughts on this acquisition? How do you see it shaping the future of the pharma industry? https://lnkd.in/dpGwRCDZ #PharmaIndustry #Healthcare #BusinessStrategy #Innovation #GlobalPharma #PharmaceuticalManagement

RV Group Enters Booming Indian Pharma Market!🏆 🔝ASEAN Pharma Giant Arrives: RV Group, a leading pharmaceutical company in ASEAN, has entered the Indian market through the acquisition of GSK's well-established brands, Celin & Septran. 🔛Leveraging Strengths: This expansion allows RV Group to tap into India's massive pharmaceutical sector and strong R&D capabilities, boosting their global presence. 💯Commitment to Quality: The acquisition strengthens RV Group's ability to deliver high-quality and affordable healthcare solutions to a wider patient population. ✴Legacy Brands Open Doors: Celin and Septran's brand recognition provides RV Group with a strong foundation to succeed in the Indian market. ⏭Future Focus: This move reflects RV Group's ambition to become a major player in the global pharmaceutical landscape, with potential expansion into the US and Europe. #RVGroup #Pharma #India #Acquisition #Healthcare #GSK

Our Annual Report is fresh off the press! Grünenthal's people have transformed our company over the last few years, uniquely positioning us to meet the increased demand for better pain treatments. 🌎 Our medicines today help more patients than ever before as we are growing our footprint in key pharmaceutical markets, especially in the United States 🧬 We advanced key R&D projects, creating one of the strongest pain-focused pipelines in the industry 📦 We ensured uninterrupted supply of medicines to patients in over 100 countries 💊 Through strategic acquisitions, we expanded our portfolio of established medicines This momentum put us in an excellent position to deliver outstanding business performance.  Read more about our story of transformation in our Annual Report: https://bit.ly/3UklN84 #WeAreGrünenthal #WorldFreeofPain

Over the three decades since1994, #FosunPharma, a global innovation-driven pharmaceutical and healthcare industry group, has built a strong global operation network in multiple dimensions, including innovative R&D, licensed-in projects, production and operation as well as commercialization. On the occasion of the 30th anniversary of Fosun Pharma, let's take a look at Fosun Pharma's globalization layout and the insights of our global partners. #globalization #Innovation #anniversary

𝗖𝗶𝗽𝗹𝗮 𝗮𝗻𝗱 𝗔𝗹𝗸𝗲𝗺 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀 𝗡𝗲𝗮𝗿𝗶𝗻𝗴 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗠𝗧 Cipla and Alkem Laboratories Ltd. are in the final stages of negotiations to acquire Sahajanand Medical Technologies, a significant move that could reshape their market positions in the pharmaceutical industry. This acquisition is part of both companies' strategies to enhance their product portfolios and expand their reach in various therapeutic segments. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻: The deal is expected to strengthen Cipla's and Alkem Laboratories Ltd.'s capabilities in the specialty pharmaceuticals sector, allowing them to offer a broader range of products. 𝗠𝗮𝗿𝗸𝗲𝘁 𝗜𝗺𝗽𝗮𝗰𝘁: Both companies aim to leverage Sahajanand Medical Technologies's existing infrastructure and market presence, which could lead to increased competitiveness in the rapidly evolving healthcare landscape. 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗗𝗲𝘁𝗮𝗶𝗹𝘀: While specific financial terms of the acquisition have not been disclosed, analysts suggest that this move aligns with the ongoing trend of consolidation within the pharmaceutical industry. 𝗙𝘂𝘁𝘂𝗿𝗲 𝗣𝗿𝗼𝘀𝗽𝗲𝗰𝘁𝘀: This acquisition is anticipated to pave the way for innovation and improved access to medications, benefiting patients and healthcare providers alike. As Cipla and Alkem Laboratories Ltd. finalize this acquisition, it highlights the ongoing evolution within the pharmaceutical sector, driven by strategic partnerships and expansions. For further details, you can read the full article here (The Economic Times)- https://lnkd.in/eat3Ms6K 💬 What are your thoughts on how this acquisition will impact the pharmaceutical landscape? #Pharmaceuticals #Cipla #Alkem #Acquisition #Healthcare #SMT #MarketTrends #Biotech #NIPER #NIPERM #MedTech #DOMD

BF Biosciences Ltd. (BFBIO), a key player in Pakistan's biotech pharmaceutical sector is up for public listing. BFBIO intends to issue 25.0Mn shares (28.3% of the post IPO shares) at a floor price of PKR 55/share (transaction size of PKR 1.375Bn). Purpose of the Issue: BFBIO is aiming to (1) incur CAPEX, (2) obtain export certifications, and (3) manage working capital to meet operational requirements. Of the IPO proceeds, PKR 560Mn will be apportioned to expand its business to improve manufacturing efficiencies and broaden product base. The company is also focused on acquiring PIC/S and SRA certifications for international sales of its products. We like the investment case of BFBIO based on the following premises: (1) enhancement in capacity which will drive topline growth, (2) attractive valuations both in terms of replacement cost and relative valuations, (3) strong brand presence, (4) momentous potential in export market, and (5) availability of cheap TERF financing in a high interest rate environment. It is worthwhile mentioning that unlike recent IPO’s where companies intend to raise capital to finance expansions, in the case of BFBIO the expansion project has already been in full swing since FY20. The project is now nearing completion and thus the gestation period is particularly small and return generation should be swift for an IPO investor. BF Biosciences [A Subsidiary Of Ferozsons Laboratories Limited] Ferozsons Laboratories Limited Abbott AGP Limited GSK Haleon Highnoon Hoechst Pakistan Limited Citi Pharma Limited Otsuka Pharmaceutical Co., Ltd. The SEARLE Company Ltd. Macter International Limited IBL HEALTHCARE

🔍 SUN PHARMA ’s Acquisition of Taro Pharmaceuticals SUN PHARMA Industries, one of India’s leading pharmaceutical companies, has announced its intention to acquire all outstanding shares of Taro Pharmaceuticals Industries, a prominent US generics drugmaker. The deal is set at a price of $43 per share in cash, solidifying SUN PHARMA ’s global presence and strategic growth1. 🌐 Key Takeaways: Strategic Move: SUN PHARMA ’s acquisition of Taro Pharmaceuticals underscores its commitment to expanding its footprint in the international market. Generics Expertise: Taro Pharmaceuticals brings a wealth of expertise in generic drug development and manufacturing. Global Impact: This merger bridges the gap between Indian and US pharmaceutical markets, fostering collaboration and innovation. 🚀💊 #PharmaIndustry #MergersAndAcquisitions #SunPharma #TaroPharma #cipla #abbott #Pharma #Pharmacy